United Therapeutics (NASDAQ: UTHR) reported Q4 adjusted EPS of $3.21, $1.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $346.4 million versus the consensus estimate of $336.22 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.